



**For Immediate Release:**

**Date: January 4, 2017**

**EternoGen Aesthetics LLC opens offices at Massachusetts Medical Device Development Center (M2D2) to improve manufacturing efficiencies and capitalize on being part of the world's preeminent Biotech Hub**

**LOWELL, Massachusetts – January 4<sup>TH</sup>, 2017** – EternoGen Aesthetics LLC (EA), developer and manufacturer of advanced collagen scaffolds to deliver Bio Dermal Restoration, announced today the opening of new offices within the Massachusetts Medical Device Development Center (M2D2). The new office will allow the company to be close to their manufacturing site in Massachusetts and to capitalize on the skill base that comes with the dense clustering of similar firms in the region.

2017 stands to be a pivotal year for EA with the impending European approval and launch of its first in class Bio Dermal Restoration product Cellifique® which is positioned to revolutionize the \$2B global dermal filler market. Cellifique is the approved brand name of Rapidly Polymerizing Collagen and EA's first of a rich pipeline of products designed to produce natural lasting aesthetic results through directly restoring dermal tissue lost with age as opposed to filling wrinkles with foreign substances.

EA worked closely with the Massachusetts Life Sciences Center (MLSC) on considering location options in Massachusetts to be close to their contract manufacturer, Berkshire Sterile Manufacturing (BSM) in Lee, Massachusetts. BSM is a leader in sterile manufacturing processes. EA plans to utilize the MLSC's Internship Challenge program to recruit local talent in line with their expansion plans.

"We are delighted to announce this critical milestone for EA as we gear up for the European launch of Cellifique in 2017" explains Anna Tenstam, EA's CEO. "Having an office close to our manufacturing site will significantly improve our operational efficiencies as we scale-up production. Equally Massachusetts has one of the largest concentrations of biotech and med tech activity in the world and being a part of this will give us access to some of the leading scientific and industry talent as we expand."

"EternoGen Aesthetics LLC's decision to open offices here speaks to the benefits companies gain from being located within Massachusetts's biotech cluster, and being in close proximity to advanced manufacturing partners," said Housing and Economic Development Secretary Jay Ash. "The M2D2 Center has once again proven to be an extraordinary asset in attracting new and established companies to the Commonwealth."

"We welcome Eternogen to Massachusetts, and look forward to supporting the company's growth here," said Travis McCreedy, President & CEO of the MLSC. "We are pleased to see them taking advantage of the exceptional resources offered by both M2D2 and Berkshire Sterile Manufacturing, joining a growing and vibrant concentration of innovative medical device companies in the Merrimack Valley." In 2014, M2D2 received \$5 million in grant funding from the MLSC's Competitive Capital Program to support the expansion of their incubator facilities.

“We are pleased to welcome Eternogen to the M2D2 incubator,” said Stephen McCarthy, Founder & Director of M2D2. “Through the resources of UMass Lowell, the UMass Medical School, and in the Massachusetts entrepreneurial ecosystem as a whole, we look forward to working with Eternogen and helping to advance their technology toward commercialization.”

For more information about EternoGen Aesthetics please visit [www.eternogen.com](http://www.eternogen.com)

**About Cellifique® Rapidly Polymerizing Collagen** - RPC Pure-Collagen is a proprietary, clear and viscous "solution" comprised of pure collagen molecules. The solution is easily injected through 30 Gauge for precise placement to immediately achieve the desired correction. Upon exposure to physiological fluids the collagen solution rapidly converts into a stable opaque scaffold composed of natural collagen fibrils. The stabilized scaffold provides a natural structure for host cell infiltration and integration with the surrounding dermal tissue to deliver Bio Dermal Restoration. The scaffold is slowly resorbed by the body.

**About EternoGen Aesthetics.** EternoGen Aesthetics is a commercial stage Medical Device Company that has developed a transformative pipeline of advanced collagen scaffolds to deliver Bio-Dermal Restoration. EternoGen was founded in 2009 by an award winning academic research group from the University of Missouri. The management team is a group of proven industry veterans with strong connections needed for successful commercialization into the aesthetic medicine market.

**About M2D2:** M2D2 is an established incubator for medical device and biotechnology companies. M2D2, the Massachusetts Medical Device Development Center, is a joint initiative of the Lowell and Worcester campuses of the UMass system. Its aim is to help new biotech and medical device entrepreneurs develop products every step of the way, from proof-of-concept to commercialization. Its affiliated faculty and staff have assisted more than 100 start-up companies and entrepreneurs since the program kicked off in the spring of 2007.

**About the Massachusetts Life Sciences Center:** The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, education, research & development, and commercialization. The MLSC is charged with implementing a \$1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation's most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences. For more information visit [www.masslifesciences.com](http://www.masslifesciences.com).

*MLSC Disclaimer: This announcement is not intended to be a commercial endorsement of any products or services provided or developed by the entities referenced in this release.*

Contact for EternoGen:

Charles Weatherstone, Chief Commercial Officer  
[cweatherstone@eternogen.com](mailto:cweatherstone@eternogen.com), +44 7557 358491

Contact For MLSC:

Angus McQuilken, VP for Communications & Marketing  
[amcquilken@masslifesciences.com](mailto:amcquilken@masslifesciences.com), 617-921-7749

Contact for M2D2:

Christine Gillette  
[Christine\\_Gillette@uml.edu](mailto:Christine_Gillette@uml.edu), 978-934-2209